IBDEI3C1 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,2523,0)
 ;;=ACSC ASTHMA/BRONCHITIS/COPD^5^193
 ;;^UTILITY(U,$J,358.4,2524,0)
 ;;=ACSC CHF^6^193
 ;;^UTILITY(U,$J,358.4,2525,0)
 ;;=ACSC DEHYDRATION^7^193
 ;;^UTILITY(U,$J,358.4,2526,0)
 ;;=ACSC DIABETES TYPE 1^8^193
 ;;^UTILITY(U,$J,358.4,2527,0)
 ;;=ACSC DIABETES TYPE 2^9^193
 ;;^UTILITY(U,$J,358.4,2528,0)
 ;;=ACSC HYPERTENSION^10^193
 ;;^UTILITY(U,$J,358.4,2529,0)
 ;;=ACSC INFECTIOUS GASTROENTERITIS^11^193
 ;;^UTILITY(U,$J,358.4,2530,0)
 ;;=ACSC PNEUMONIA^12^193
 ;;^UTILITY(U,$J,358.4,2531,0)
 ;;=ACSC UTI^13^193
 ;;^UTILITY(U,$J,358.4,2532,0)
 ;;=ACSC VIRAL ENTERITIS^14^193
 ;;^UTILITY(U,$J,358.4,2533,0)
 ;;=E-CIG/VAPE LUNG INJURY^23^193
 ;;^UTILITY(U,$J,358.4,2534,0)
 ;;=ACSC ACUTE KIDNEY FAILURE^1^194
 ;;^UTILITY(U,$J,358.4,2535,0)
 ;;=ACSC ANGINA^2^194
 ;;^UTILITY(U,$J,358.4,2536,0)
 ;;=ACSC ASTHMA/BRONCHITIS/COPD^3^194
 ;;^UTILITY(U,$J,358.4,2537,0)
 ;;=ACSC CHF^4^194
 ;;^UTILITY(U,$J,358.4,2538,0)
 ;;=ACSC DEHYDRATION^5^194
 ;;^UTILITY(U,$J,358.4,2539,0)
 ;;=ACSC DIABETES TYPE 1^6^194
 ;;^UTILITY(U,$J,358.4,2540,0)
 ;;=ACSC DIABETES TYPE 2^7^194
 ;;^UTILITY(U,$J,358.4,2541,0)
 ;;=ACSC HYPERTENSION^8^194
 ;;^UTILITY(U,$J,358.4,2542,0)
 ;;=ACSC INFECTIOUS GASTROENTERITIS^9^194
 ;;^UTILITY(U,$J,358.4,2543,0)
 ;;=ACSC PNEUMONIA^10^194
 ;;^UTILITY(U,$J,358.4,2544,0)
 ;;=ACSC UTI^11^194
 ;;^UTILITY(U,$J,358.4,2545,0)
 ;;=ACSC VIRAL ENTERITIS^12^194
